Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209,129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, Fu L, Ma B, Ye S, Sun J, Lu W, Liu Z, Chen D, Cheng Z, Liu H, Zhang T, Zou J. Weng J, et al. Among authors: wang x. Diabetes Obes Metab. 2021 Aug;23(8):1754-1764. doi: 10.1111/dom.14389. Epub 2021 Apr 14. Diabetes Obes Metab. 2021. PMID: 33769656 Clinical Trial.
Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study).
Du J, Liang L, Fang H, Xu F, Li W, Shen L, Wang X, Xu C, Bian F, Mu Y. Du J, et al. Among authors: wang x. Diabetes Obes Metab. 2017 Nov;19(11):1513-1520. doi: 10.1111/dom.12942. Epub 2017 Jul 6. Diabetes Obes Metab. 2017. PMID: 28296055 Clinical Trial.
Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study.
Ji L, Sun N, Zhang Y, Zhang L, Shen S, Wang X, Li Q, Dong L, Ren W, Qi L, Li Y, Yan S, Cheng W, Kuang H, Li G. Ji L, et al. Among authors: wang x. Diabetes Obes Metab. 2020 Feb;22(2):158-166. doi: 10.1111/dom.13884. Epub 2019 Oct 24. Diabetes Obes Metab. 2020. PMID: 31512365 Clinical Trial.
Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open-label, randomized controlled trial (BEYOND VII).
Ji L, Wan H, Wen B, Wang X, Wang J, Bian R, Pang W, Tian J, Wang Y, Bian F, Gao Z, Condoleon A, Feng W, Zhang X, Cui N. Ji L, et al. Among authors: wang x, wang j, wang y. Diabetes Obes Metab. 2020 May;22(5):838-846. doi: 10.1111/dom.13967. Epub 2020 Feb 18. Diabetes Obes Metab. 2020. PMID: 31944546 Free PMC article. Clinical Trial.
Impact of baseline characteristics on glycemic effects of add-on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus.
Fang H, Xu F, Du J, Liang L, Li W, Shen L, Wang X, Xu C, Bian F, Mu Y. Fang H, et al. Among authors: wang x. J Diabetes Investig. 2020 Jul;11(4):896-905. doi: 10.1111/jdi.13224. Epub 2020 Mar 27. J Diabetes Investig. 2020. PMID: 32020731 Free PMC article. Clinical Trial.
Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial.
Zhang L, Zhang Y, Shen S, Wang X, Dong L, Li Q, Ren W, Li Y, Bai J, Gong Q, Kuang H, Qi L, Lu Q, Cheng W, Liu Y, Yan S, Wu D, Fang H, Hou F, Wang Y, Yang Z, Lian X, Du J, Sun N, Ji L, Li G; China Diabetes Prevention Program Study Group. Zhang L, et al. Among authors: wang x, wang y. Lancet Diabetes Endocrinol. 2023 Aug;11(8):567-577. doi: 10.1016/S2213-8587(23)00132-8. Epub 2023 Jul 3. Lancet Diabetes Endocrinol. 2023. PMID: 37414069 Clinical Trial.
209,129 results
You have reached the last available page of results. Please see the User Guide for more information.